Buprenorphine
Buprenorphine has been studied in 3 papers since 2017: 1 trial in people, 2 in animals. The newest paper, Nov 2, 2021: “Establishment of a Novel Method for Spinal Discectomy Surgery in Elderly Rats in an In Vivo Spinal Fusion Model”.
“We found a significant increase in TST for patients who received active buprenorphine compared with those who received active paracetamol (see Table ).”
None of its findings points the other way.
- 2 independent labs in 3 countries
- 8 trials, none about aging, 1 with no results posted
- Funders: GC Rieber Fondene and 5 more
- 1 of 2 findings with company ties
- Human trial1
- Animals2
Studies in people
1 study gave buprenorphine to people and measured what changed.
up: Increases total sleep time
Randomized trial106 people76% were femalemean age was 85.5 years (SD = 7.3)1 week
Nursing home patients with dementia and depression
International journal of geriatric psychiatry, Dec 28, 2017
What did studies of Buprenorphine find?
2Studies of Buprenorphine measured 2 outcomes; the most studied are post-operative cognitive dysfunction (1 study) and total sleep time (1).
Post-operative cognitive dysfunction
no changein rats1
1 study
Post-operative cognitive dysfunction
no changein rats1
Buprenorphine showed no clear effect on post-operative cognitive dysfunction in rats (tibial fracture surgery model of POCD).
“but not in animals which were exposed to anesthesia alone or underwent the surgery and received buprenorphine”
Animalstibial fracture surgery model of POCD
Research SquarePreprint
Total sleep time
upin humans1
1 study
Total sleep time
upin humans1
Buprenorphine increases total sleep time in humans (compared with active paracetamol).
“We found a significant increase in TST for patients who received active buprenorphine compared with those who received active paracetamol (see Table ).”
Human trialcompared with active paracetamol1 week
International journal of geriatric psychiatry
Who is developing Buprenorphine?
1 company: Atea Pharmaceuticals.
- Companies
- Atea PharmaceuticalsPhase 1
Trial sponsors
Company1 trialPhase 4136 people
Company1 trialPhase 3101 people
BioDelivery Sciences International
Company1 trialPhase 239 people
Company1 trialPhase 130 people
Company1 trialPhase 120 people
Wake Forest University Health Sciences
1 trialPhase 4282 people
University of Alabama at Birmingham
1 trialPhase 430 people
National Institute on Drug Abuse
1 trialPhase 2